Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Entities / Companies / Roivant Sciences
Entity

Roivant Sciences

Tracked across 3 events · 52 articles · First seen May 23, 2025 · Last active Jul 06, 2026

Sentiment
-7
Attention
4
Events
3
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (3)
4 -20
Business
Roivant Brepocitinib Expansion, Immunovant Batoclimab Failure
Impact: Roivant Sciences announced the expansion of its brepocitinib program and the failure of Immunovant's batoclimab Phase 3 studies, which could negatively impact its stock.
Apr 02, 2026 · 16 articles
4 0
Domestic
Ohio, Indiana, Michigan Primary Elections
Impact: Roivant Sciences, a subsidiary of Roivant Sciences, settled with Moderna for $2.2 billion over unauthorized use of its patents in COVID vaccines.
May 02, 2026 · 30 articles
4 0
Business
AbCellera Appoints Lynn Seely to Board
Impact: Dr. Lynn Seely previously served as president, CEO, and board member of Roivant Sciences Inc., where she commercialized innovative therapies.
Apr 20, 2026 · 6 articles
Relationships (2)
Organon & Co. target ↔ Roivant Sciences Roivant Sciences was acquired by Organon & Co. for $1.2 billion in October 2024.
Organon & Co. acquirer ↔ Roivant Sciences Organon & Co. acquired Roivant Sciences for $1.2 billion in October 2024, a tran
ERGEN INTELLIGENCE
Track Roivant Sciences live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.